Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOXIL and Ashwagandha in Recurrent Ovarian Cancer
NCT05610735Phase 2Recruiting
- Start
- Sep 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of withania somnifera in ovarian cancer. Primary endpoint: Progression-Free Survival up to 4 years. Started Sep 2024; status: recruiting.
02
Drugs
withania somnifera
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05610735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610735.